John Burr, MD
Pulmonary Disease · Normal, ILNPI 1770535940
Payments from drug & device makers
Across 190 payments — averaging $61.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Jazz Pharmaceuticals Inc.$1K
- Inspire Medical Systems, Inc.$555
- GSK$468
- Boehringer Ingelheim$467
- AstraZeneca$424
- plus $2K from 30 others
What the payments were for
- Travel & lodging$9468%
- Food & beverage$5,19744%
- Education$5,56748%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 10 | $6,663 |
| Jazz Pharmaceuticals Inc. | 24 | $1,191 |
| Inspire Medical Systems, Inc. | 8 | $555 |
| GSK | 27 | $468 |
| Boehringer Ingelheim | 17 | $467 |
| AstraZeneca | 24 | $424 |
| Vapotherm Inc | 6 | $149 |
| Insmed, Inc. | 6 | $143 |
| Axsome Therapeutics, Inc. | 6 | $138 |
| Pinnacle Biologics, Inc | 1 | $136 |
| United Therapeutics Corporation | 1 | $123 |
| Avadel CNS Pharmaceuticals, LLC | 6 | $120 |
| Amgen | 5 | $115 |
| Viatris Specialty LLC | 4 | $106 |
| Harmony Biosciences LLC | 3 | $92 |
| Genentech USA, Inc. | 1 | $91 |
| Sanofi | 4 | $79 |
| Verona Pharma, Inc. | 3 | $74 |
| Itamar Medical Inc | 1 | $72 |
| Boston Scientific | 2 | $59 |
| Edwards Lifesciences | 1 | $58 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $51 |
| Regeneron Healthcare Solutions, Inc. | 3 | $47 |
| Grifols USA, LLC | 2 | $43 |
| Electromed, Inc. | 8 | $38 |
| Mylan Specialty L.p. | 2 | $37 |
| Bayer | 2 | $35 |
| Lilly USA, LLC | 1 | $27 |
| Breas Medical, Inc. | 1 | $23 |
| Resmed Corp | 1 | $20 |
| Fisher & Paykel Healthcare Inc | 1 | $18 |
| Merck | 1 | $16 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Janssen Research & Development, LLC | 3 | $15 |
| Johnson & Johnson | 1 | $12 |
| Ambu Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,725 in reported general payments places this provider in the 75th percentile of 539 pulmonary disease providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 164 | $127,611 |
| NucalaMepolizumab | 15 | $55,332 |
| EliquisApixaban | 25 | $31,125 |
| Breo ElliptaFluticasone/Vilanterol | 28 | $17,943 |
| Arnuity ElliptaFluticasone Furoate | 62 | $17,681 |
| Spiriva HandihalerTiotropium Bromide | 24 | $16,936 |
| Spiriva RespimatTiotropium Bromide | 12 | $13,428 |
| Tiotropium Bromide | 12 | $12,677 |
| SymbicortBudesonide/Formoterol Fumarate | 31 | $10,420 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $10,006 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 55 | $9,716 |
| Incruse ElliptaUmeclidinium Bromide | 13 | $7,558 |
| DuleraMometasone/Formoterol | 14 | $6,796 |
| Advair HfaFluticasone Propion/Salmeterol | 12 | $3,996 |
| Wixela InhubFluticasone Propion/Salmeterol | 27 | $3,366 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Breo Ellipta, Arnuity Ellipta, Anoro Ellipta | $468 | $236,131305 claims |
| Boehringer IngelheimSpiriva Respimat | $467 | $13,42812 claims |
| AstraZenecaSymbicort | $424 | $10,42031 claims |
| MerckDulera | $16 | $6,79614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 539 pulmonary disease providers in Illinois.
Other pulmonary disease in Normal
- Douglas HogarthChicago$3.1M
- Manu JainChicago$1.9M
- Momen WahidiChicago$1.2M
- Shashi BellamEvanston$1.2M
- Marilyn GlassbergMaywood$1000K
- Steven WhiteChicago$989K
- Ravi KalhanChicago$831K
- Patrick WhittenPeoria$812K
- Jane Dematte DamicoChicago$811K
- Septimiu MurguChicago$804K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.